Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters
Authors:
- 1 April 2007
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 34 (3) , 239-246
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson DiseaseJournal of Cerebral Blood Flow & Metabolism, 2006
- Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transportersNuclear Medicine and Biology, 2006
- Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementiaMovement Disorders, 2006
- Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson’s disease?European Journal of Nuclear Medicine and Molecular Imaging, 2002
- AgainstEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Specificity of Diastereomers of [99mTc]TRODAT-1 as Dopamine Transporter Imaging AgentsJournal of Medicinal Chemistry, 1998
- Presynaptic monoaminergic vesicles in Parkinson's disease and normal agingAnnals of Neurology, 1996
- The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatmentsProgress in Neurobiology, 1996
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transportersNuclear Medicine and Biology, 1996
- IPT: A novel iodinated ligand for the CNS dopamine transporterSynapse, 1995